TWi Pharma of Taiwan Gains US Approval for Calcium-Channel Blocker

TWi Pharma of Taiwan was granted US approval to market a generic version of Procardia XL® (nifedipine) Extended Release Tablets. Procardia XL is member of the calcium-channel blocker class of drugs, administered to treat high blood pressure and chest pain. TWi Pharma makes generics that are difficult to produce or have novel delivery systems, all of which are intended only for the US market. The nifedipine product is the company’s first to be approved. More details.... Stock Symbol: (TWO: 4180) Share this with colleagues: // //